GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.00
Bid: 96.00
Ask: 100.00
Change: -7.00 (-6.80%)
Spread: 4.00 (4.167%)
Open: 103.00
High: 96.00
Low: 96.00
Prev. Close: 103.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

Mon, 31st Oct 2022 19:58

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

4Global PLC - London-based data, services and software for sporting events and the promotion of physical activity - Secures a GBP4 million contract over five years with an unnamed "major sporting infrastructure project" for an unspecified city in the Middle East. "Approximately GBP600,000 of the project is expected to be delivered and recognised in the current financial year and the project includes an opportunity for additional scope throughout the engagement," it says.

----------

James Cropper PLC - paper products manufacturer based in Cumbria, England - Says achieves break-even position in half-year to September 24. Revenue rises 26% year-on-year, though rising costs put pressure on bottom-line. Says energy costs have more than doubled. "The impact of inflationary pressures had been mitigated in the first part of the year by the application of energy surcharges but energy prices again spiked from late July and again in August. At the same time raw materials (which represent a larger proportion of overall costs) have been subject to unprecedented inflationary headwinds, rising 20% over the same period," James Cropper says. Adds: "The second half of the year shows a recovery through aggressive pricing actions and surcharges, supported by the recently announced government support on energy prices. Each division is projecting volume growth over the second half. Order books are full and the company is focused on a range of enabling actions to build a solid foundation for continued future growth." Company cuts annual outlook, however. Now expects full-year adjusted pretax profit of GBP2.0 million, versus previous market expectations of GBP5.4 million.

----------

Ncondezi Energy Ltd - power development company - Says feasibility study for battery energy storage system project confirms it is "technically viable and attractive". Study notes potential for 20% to 30% capital expenditure savings. Also says project can deliver first power of up to 60 megawatts within 18 months of financial close, with full 300 megawatts over 28 months. Ncondezi says has extended capital runway to November. Says it needs and intends to secure additional funding before the end of November, with "various options available and under consideration". This includes the potential additional tranche of GBP150,000 that may be available to it under the terms of the convertible loan facility it announced back in mid-September.

----------

Vast Resources PLC - London-based miner with projects in Romania and Zimbabwe - Revenue in 12 months ended April 30 surges to USD3.8 million from USD896.000. Pretax loss, however, widens to USD15.5 million from USD7.7 million. Posts exchange loss of GBP3.8 million, compared to GBP2.6 million gain a year earlier. In addition, vast says it has raised GBP1.5 million in placing of 652.0 million shares at 0.225 pence each. Vast adds: "The net cash raised from the placing will ensure sufficient levels of working capital are maintained to meet the company’s corporate obligations as well as cover certain transaction costs linked to possible new opportunities the company is investigating."

----------

Rockhopper Exploration PLC - Salisbury, England-based oil & gas exploration and production company - Updates on arbitration of dispute with Italian government. On Friday, Italy submitted an application to the International Centre for Settlement of Investment Disputes seeking to annul a recent award to Rockhopper, and requested a provisional stay of the enforcement of the EUR190 million award. Chief Executive Officer Samuel Moody calls the news "disappointing", adding: "Based on legal advice we believe annulment proceedings are likely to take approximately 18 to 24 months, albeit interest will commence accruing again in December 2022. We remain confident in the strength of our case, as was reflected in the unanimous decision underpinning the Award in August, and very much hope and believe the annulment request will be rejected in due course." Rockhopper says it has a non-binding offer in place for funding to fight the annulment and enforce the award.

----------

Alba Mineral Resources PLC - explorer with assets in Greenland, Ireland and the UK - Submits to watchdog an updated permit application to dewater the Llechfraith Shaft. In November 2021, the Natural Resources Wales regulator refused to grant Alba an application to dewater the Llechfraith Shaft. Since then, Alba has submitted to NRW additional data and analysis.

----------

R&Q Insurance Holdings Ltd - Bermuda-based specialty non-life insurer formerly known as Randall & Quilter Investment - Says gross written premiums in Program Management business up 83% to USD1.3 billion in nine months ended September 30, from USD714 million a year earlier. Programme fee income doubles to USD60 million.

----------

Blue Star Capital PLC - Sussex-based investment company focused on e-sports, payments and technology - Investee Dynasty Gaming & Media Pte Ltd signs distribution agreement with Indosat Ooredoo Hutchison, a telecommunications company, with about "100 million subscribers in Indonesia". Dynasty to offer play-to-earn games, developed by Pioneer Media Holdings Inc, to IOH. Pioneer and Dynasty have a game publishing agreement. Deal allows Dynasty to exclusive license to publish, market, promote and distribute Pioneer games in southeast Asia, India, and Australia.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Moves to second level of Phase I/II BEXMAB study, which is probing bexmarilimab in tandem with standard of care to treat hematological malignancies. Hematological malignancies are blood cancers. Faron says: "All first-stage cohort patients are alive. The longest treated patient at three cycles has revealed partial response as observed by reduced cancer activity with reduced blast (cancer cell) counts and normalised blood cell counts. Initial data from patients dosed with bexmarilimab also show a significant reduction in levels of soluble Clever-1 protein in the blood of treated patients." Dose will now be escalated.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
12 Jul 2019 10:20

Faron Pharma Pleased By MATINS Progress And Plans To Increase Capacity

(Alliance News) - Faron Pharmaceuticals Oy said on Friday its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries.The

Read more
26 Jun 2019 11:52

Faron Pharmaceuticals Says Traumakine Study Hindered By Steroid Use

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a

Read more
14 Jun 2019 11:54

Faron Pharmaceuticals' Analysis Explains "Disappointing" Prior Trial

(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in

Read more
14 Jun 2019 10:37

Faron Pharmaceuticals reports 'significant' findings from YODA study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.

Read more
24 May 2019 13:34

Faron Pharma Finance Head Wichmann Steps Down, Hanninen Replaces

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said

Read more
24 May 2019 11:50

Faron appoints new CFO after some internal shuffling

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.

Read more
14 May 2019 14:16

Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)

LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares

Read more
7 May 2019 11:44

Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical

Read more
2 May 2019 17:30

Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said

Read more
30 Apr 2019 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock

Read more
29 Apr 2019 15:46

Faron Gets Results Of Traumakine Study From Japanese Licensing Partner

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for

Read more
11 Apr 2019 12:13

Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial

LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will

Read more
11 Apr 2019 11:22

Faron Pharmaceuticals upbeat on latest info from MATINS trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.

Read more
26 Mar 2019 15:52

UPDATE: Faron Pharmaceuticals Raises EUR3.1 Million In Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued

Read more
26 Mar 2019 12:05

Faron Pharmaceuticals Optimistic For Traumakine As It Plans Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.